These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17881097)

  • 1. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.
    Hammerschmidt T; Bisanz H; Wutzler P
    Vaccine; 2007 Oct; 25(42):7307-12. PubMed ID: 17881097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ; de Melker HE; Stolk EA; de Wit GA; Kimman TG
    Vaccine; 2006 Sep; 24(37-39):6288-99. PubMed ID: 16790302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
    Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
    Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined vaccine against measles, mumps, rubella and varicella and recommendations for varicella immunization in Italy?].
    Papa R; Spinelli R; Zaratti L; Franco E
    Ig Sanita Pubbl; 2007; 63(6):715-22. PubMed ID: 18216886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
    Bonanni P; Boccalini S; Bechini A; Banz K
    Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Mar; 57(10):258-60. PubMed ID: 18340332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic analysis of the universal varicella vaccination program in the United States.
    Zhou F; Ortega-Sanchez IR; Guris D; Shefer A; Lieu T; Seward JF
    J Infect Dis; 2008 Mar; 197 Suppl 2():S156-64. PubMed ID: 18419391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
    Knuf M; Neiss A; Wutzler P
    Klin Padiatr; 2006; 218(4):203-12. PubMed ID: 16819701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chickenpox: sufficient reasons for the introduction of vaccination].
    Rümke H; de Groot R
    Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2630-2. PubMed ID: 17205937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.
    Streng A; Liese JG
    Vaccine; 2014 Feb; 32(8):897-900. PubMed ID: 24412300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine.
    Vesikari T; Sadzot-Delvaux C; Rentier B; Gershon A
    Pediatr Infect Dis J; 2007 Jul; 26(7):632-8. PubMed ID: 17596807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspective on live varicella vaccine.
    Gershon AA; Katz SL
    J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.